The contribution of factor V Leiden and prothrombin G20210A mutation to the risk of central venous catheter-related thrombosis

Haematologica

Volumn 89, Issue 2, 2004, Pages 201-206

  Van Rooden, Cornelis J ^a   Rosendaal, Frits R ^a   Meinders, A Edo ^a   Van Oostayen, Jacques A ^a   Van Der Meer, Felix J M ^a   Huisman, Menno V ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Central venous catheter; Doppler ultrasound; Genetics; Thrombophilia; Thrombosis

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 5 LEIDEN; HEPARIN; NADROPARIN; PROTHROMBIN; BLOOD CLOTTING FACTOR 5;

ADOLESCENT; ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLOOD CLOTTING DISORDER; CANCER; CENTRAL VENOUS CATHETER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOPPLER ECHOGRAPHY; DOUBLE BLIND PROCEDURE; FEMALE; GENE MUTATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; RISK ASSESSMENT; RISK FACTOR; THROMBOSIS; VEIN THROMBOSIS; VIDEORECORDING; 5' UNTRANSLATED REGION; ACTIVATED PROTEIN C RESISTANCE; CENTRAL VENOUS CATHETERIZATION; CLASSIFICATION; COHORT ANALYSIS; ECHOGRAPHY; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; HOSPITALIZATION; INFECTION; MIDDLE AGED; NEOPLASM; NETHERLANDS; POINT MUTATION; PROSPECTIVE STUDY; SINGLE BLIND PROCEDURE; THROMBOPHILIA;

5' UNTRANSLATED REGIONS; ACTIVATED PROTEIN C RESISTANCE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; CATHETERIZATION, CENTRAL VENOUS; COHORT STUDIES; FACTOR V; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INCIDENCE; INFECTION; MALE; MIDDLE AGED; NEOPLASMS; NETHERLANDS; POINT MUTATION; PROSPECTIVE STUDIES; PROTHROMBIN; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD; THROMBOPHILIA; THROMBOSIS;

EID: 2942603511     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Raad I. Intravascular-catheter-related infections. Lancet 1998;351:893-8.
2. Horattas MC, Wright DJ, Fenton AH, Evans DM, Oddi MA, Kamienski RW, et al. Changing concepts of deep venous thrombosis of the upper extremity-report of a series and review of the literature. Surgery 1988;104:561-7.
3. Bona RD. Thrombotic complications of central venous catheters in cancer patients. Semin Thromb Hemost 1999;25:147-55.
4. Monreal M, Raventos A, Lerma R, Ruiz J, Lafoz E, Alastrue A, et al. Pulmonary embolism in patients with upper extremity DVT associated to venous central lines - a prospective study. Thromb Haemost 1994;72:548-50.
5. Emmerich J, Rosendaal FR, Cattaneo M, Margaglione M, De Stefano V, Cumming T, et al. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism - pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Thromb Haemost 2001;86:809-16.
6. Fijnheer R, Paijmans B, Verdonck LF, Nieuwenhuis HK, Roest M, Dekker AW. Factor V Leiden in central venous catheter-associated thrombosis. Br J Haematol 2002;118:267-70.
7. Ratcliffe M, Broadfoot C, Davidson M, Kelly KF, Greaves M. Thrombosis, markers of thrombotic risk, indwelling central venous catheters and antithrombotic prophylaxis using low-dose warfarin in subjects with malignant disease. Clin Lab Haematol 1999;21:353-7.
8. Riordan M, Weiden PL. Factor V Leiden mutation does not account for central venous catheter-related thrombosis. Am J Hematol 1998;58:150-2.
9. Nowak-Göttl U, Dubbers A, Kececioglu D, Koch HG, Kotthoff S, Runde J, et al. Factor V Leiden, protein C, and lipoprotein (a) in catheter-related thrombosis in childhood: a prospective study. J Pediatr 1997;131:608-12.
10. van Rooden CJ, Monraats PS, Kettenis I, Rosendaal FR, Huisman MV. Low physician compliance of prescribing anticoagulant prophylaxis in patients with solid tumor or hematological malignancies and central vein catheters. J Throm Hemost 2003;1:1842-3.
11. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-7.
12. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3́-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88:3698-703.
13. Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995;345:152-5.
14. Koksoy C, Kuzu A, Kutlay J, Erden I, Ozcan H, Ergin K. The diagnostic value of colour Doppler ultrasound in central venous catheter related thrombosis. Clin Radiol 1995;50:687-9.
15. Knudson GJ, Wiedmeyer DA, Erickson SJ, Foley WD, Lawson TL, Mewissen MW, et al. Color Doppler sonographic imaging in the assessment of upper-extremity deep venous thrombosis. Am J Roentgenol 1990;154:399-403.
16. Baxter GM, Kincaid W, Jeffrey RF, Millar GM, Porteous C, Morley P. Comparison of colour Doppler ultrasound with venography in the diagnosis of axillary and subclavian vein thrombosis. Br J Radiol 1991;64:777-81.
17. Prandoni P, Polistena P, Bernardi E, Cogo A, Casara D, Verlato F, et al. Upper-extremity deep vein thrombosis. Risk factors, diagnosis, and complications. Arch Intern Med 1997;157:57-62.
18. Patel MC, Berman LH, Moss HA, McPherson SJ. Subclavian and internal jugular veins at Doppler US: abnormal cardiac pulsatility and respiratory phasicity as a predictor of complete central occlusion. Radiology 1999;211:579-83.
19. Rabinov K, Paulin S. Roentgen diagnosis of venous thrombosis in the leg. Arch Surg 1972;104:134-44.
20. McGee DC, Gould MK. Preventing complications of central venous catheterization. N Engl J Med 2003;348:1123-33.
21. Bern MM, Lokich JJ, Wallach SR, Bothe A Jr, Benotti PN, Arkin CF, et al. Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Ann Intern Med 1990;112:423-8.
22. Monreal M, Alastrue A, Rull M, Mira X, Muxart J, Rosell R, et al. Upper extremity deep venous thrombosis in cancer patients with venous access devices - prophylaxis with a low molecular weight heparin (Fragmin). Thromb Haemost 1996;75:251-3.
23. Geerts WH, Heit JA, Clagett GP, Pineo GF, Colwell CW, Anderson FA Jr, et al. Prevention of venous thromboembolism. Chest 2001;119 Suppl 1:132S-75S.
24. Carr KM, Rabinowitz I. Physician compliance with warfarin prophylaxis for central venous catheters in patients with solid tumors. J Clin Oncol 2000;18:3665-7.